Investing in biotechnology stocks has always required a high risk tolerance and the patience to wait years, even decades, for results. These companies drive medical innovation, developing therapies ...
TV and home video editor Ty Pendlebury joined CNET Australia in 2006, and moved to New York City to be a part of CNET in 2011. He tests, reviews and writes about the latest TVs and audio equipment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results